Sustanon 300 mg/ml Royal Pharmaceuticals

• Category: Injectable Mixed-Ester Testosterone (Research Only)
• Brand: Royal Pharmaceuticals
• Strength: 300 mg/ml total testosterone
• Ester Breakdown: T. Propionate 50 mg, T. Phenylpropionate 70 mg, T. Isocaproate 70 mg, T. Decanoate 110 mg
• Packing: 10 1 ml ampoules
• Origin: United Kingdom
• Use Notice: For laboratory and analytical research only — not for therapeutic, performance-enhancing or veterinary use.

What Is Sustanon 300?

Sustanon 300 is a mixed-ester testosterone formulation combining fast, medium, and long-acting esters in a single intramuscular injection.

This composition creates:

• A rapid onset from short-ester testosterone propionate
• Sustained release from intermediate esters (phenylpropionate, isocaproate)
• Long-term maintenance via testosterone decanoate

Mixed-ester testosterone solutions are widely referenced in medical, pharmacological and endocrine research, particularly in the context of male hypogonadism, androgen replacement therapy and anabolic-androgenic signalling.

Key Technical Characteristics

• Pharmacological class: Anabolic-androgenic steroid (androgen receptor agonist)
• Route: Intramuscular (I.M.) only
• Release pattern: Rapid–intermediate–prolonged due to ester diversity
• Approximate effective duration: ~2–3 weeks per injection (literature-based)
• WADA status: Exogenous testosterone and all esters are prohibited at all times (S1 – Anabolic Agents)

Mechanism of Action

After injection, esterases gradually hydrolyse each testosterone ester, releasing free testosterone into circulation. Free testosterone:

• Binds to androgen receptors in muscle, bone and reproductive tissues
• Modulates transcription of androgen-responsive genes
• Increases protein synthesis and nitrogen retention
• Supports erythropoiesis and increases hemoglobin/hematocrit
• Aromatises to estradiol and reduces to DHT, influencing multiple hormonal pathways

Research & Clinical Context

• Mild–severe hypogonadism: Testosterone esters restore libido, mood, bone density and body composition.
• Pharmacokinetic research: Mixed-ester profiles provide comparative data for absorption and release rates.
• Endocrine studies: Used to evaluate HPG-axis suppression and recovery mechanisms.
• Metabolic studies: Testosterone affects insulin sensitivity, lipid profiles and muscle–fat partitioning.

Note: These refer to medical literature and do not imply suitability for non-medical use.

Potential Research-Level Observations

• Increase in lean body mass and nitrogen retention
• Improved bone mineral density in hypogonadal models
• Enhanced red-blood-cell production
• Alterations in lipid profile and glucose regulation
• Clear suppression of endogenous LH/FSH signalling

Possible Adverse Effects (Research Context)

Endocrine & Reproductive

• Suppression of LH/FSH
• Reduced endogenous testosterone
• Decreased spermatogenesis; potential infertility

Cardiovascular & Haematological

• Elevated hematocrit / polycythaemia
• Lower HDL, increased LDL
• Potential blood-pressure changes

Androgenic Effects

Acne, oily skin, hair loss

Possible virilisation effects in female exposure

Hepatic & Metabolic

Injectable esters have low intrinsic hepatotoxicity but may influence metabolic enzymes

Other

Mood variation, irritability, aggression

Injection-site irritation or pain

Compliance & Regulatory Notice

• Prescription-only in most jurisdictions
• Testosterone (all forms) is a prohibited WADA S1 anabolic agent
• Handling requires adherence to local laws and research regulations

Technical Data Table

For laboratory and research use only — not for human or veterinary administration.